SEC Filing Summary: Hillstream BioPharma, Inc. (HILS)
Business Context and Reporting Period
This Form 8-K was filed on May 15, 2023, reporting events occurring on May 9, 2023. The registrant is Hillstream BioPharma, Inc., a Delaware corporation trading on The Nasdaq Stock Market LLC under the symbol HILS. The company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors increased its size to five members.
- Director Appointment: Kelly Anderson was appointed as a new director effective May 9, 2023, serving until the 2023 annual meeting of stockholders.
- Committee Assignments: Ms. Anderson was appointed to the compensation committee and the nominating and corporate governance committee.
- Audit Committee Leadership: Ms. Anderson was named chair of the audit committee, replacing Leonard Mazur.
Management Commentary and Risks
Management stated that Ms. Anderson was selected due to her over 25 years of experience in public company finance, accounting, and corporate governance. She is a Certified Public Accountant with prior executive roles at companies including Mavenlink (Kantata), Ener-Core, and Fisker Automotive. Her compensation will align with that of other non-employee directors. The filing confirms no related party transactions involving Ms. Anderson are reportable under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the effective date of the Board expansion and Ms. Anderson's term expiration at the 2023 annual meeting.
- Confirm the specific compensation structure for non-employee directors to understand the cost of this appointment.
- Review the attached press release (Exhibit 99.1) for additional context on the strategic rationale for the appointment.
- Check subsequent filings for the outcome of the 2023 annual meeting regarding Ms. Anderson's re-election.